Montana Patent of the Month – March 2024
The battle against bacterial infections, particularly those caused by the notorious Pseudomonas aeruginosa, has been a long-standing challenge in the medical field. This opportunistic pathogen is a leading cause of severe pulmonary infections, especially in individuals with cystic fibrosis (CF). One of its most formidable weapons is its ability to form resilient biofilms, rendering it highly resistant to conventional antibiotics and immune responses.
Inimmune Corporation, a pioneering biotechnology company, has been granted a patent for a new approach to combating P. aeruginosa infections by targeting the Pf-family bacteriophage, a key player in biofilm formation. Their innovation lies in the development of an antiserum containing antibodies specific to the CoaB coat protein of the Pf-family bacteriophage.
The method involves immunizing animals or human subjects with a vaccine against the Pf-family bacteriophage. This vaccine consists of an immunogenic fragment of the CoaB coat protein conjugated to an immunogenic protein, along with a pharmaceutically acceptable carrier. By introducing this vaccine, the immune system is primed to produce antibodies tailored to neutralize the CoaB coat protein, thereby disrupting biofilm formation and rendering P. aeruginosa more susceptible to treatment.
What makes this approach particularly promising is its potential to address antibiotic-resistant strains of P. aeruginosa, which pose a significant threat in clinical settings. By combining the antiserum with antibiotics, it becomes possible to enhance the efficacy of existing treatments and overcome resistance mechanisms.
This method opens doors to new avenues of research and development in the field of infectious diseases. The specificity of the antibodies and the targeted approach offer a glimpse into the future of precision medicine, where tailored therapies hold the promise of better outcomes for patients.
Inimmune’s method represents a significant leap forward in the fight against P. aeruginosa infections. By harnessing the power of antibodies against the Pf-family bacteriophage, they are paving the way for more effective and personalized treatments, ultimately improving the lives of patients battling these challenging infections.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
Are you eligible?
Why choose us?
Pass an Audit?
What is the R&D Tax Credit?
The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.
Never miss a deadline again
Stay up to date on IRS processes
Discover R&D in your industry
R&D Tax Credit Preparation Services
Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.
If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.
R&D Tax Credit Audit Advisory Services
creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.
Our Fees
Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/
Choose your state
